Gene profiling performed in the ALTTO trial reveals 5 subtypes within HER2+ #breastcancer, each with distinct prognostic and predictive implications.
Immune-enriched #tumors show the best survival. #bcsm #biomarker #precisonmedicine
www.nature.com/articles/s41...
Immune-enriched #tumors show the best survival. #bcsm #biomarker #precisonmedicine
www.nature.com/articles/s41...
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial - Nature Communications
The clinical implications of molecular heterogeneity in HER2-positive breast cancer remain to be explored. Here, the authors investigate the transcriptomic landscape of HER2-positive breast cancer pat...
www.nature.com
December 2, 2024 at 10:30 PM
Gene profiling performed in the ALTTO trial reveals 5 subtypes within HER2+ #breastcancer, each with distinct prognostic and predictive implications.
Immune-enriched #tumors show the best survival. #bcsm #biomarker #precisonmedicine
www.nature.com/articles/s41...
Immune-enriched #tumors show the best survival. #bcsm #biomarker #precisonmedicine
www.nature.com/articles/s41...
#SMC #precisiononcology #precisonmedicine #gastriccancer #zolbetuximab #NHSScotland #AstellasPharma #advancedgastriccancer #gastrooesophagealjunctioncancer #adenocarcinomatumours #biomarkers #cancerbiology #phase3clinicaltrials #SPOTLIGHT #GLOW
zurl.co/7GCPi
zurl.co/7GCPi
Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment - PharmaTimes
Decision introduces zolbetuximab for eligible patients in NHS Scotland
pharmatimes.com
January 20, 2026 at 12:04 PM